Etoricoxib benefit map Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
inflammatory pain, etoricoxib, effectiveness, safety
Main Article Content
Abstract
Inflammatory pain is a consequence of the body’s defensive reaction to infections, tissue damage or autoimmune processes. Acute pain with an inflammatory component includes numerous pain complaints with which the patient consults a doctor. A key element in the treatment of inflammatory pain is the proper selection of medications. In inflammatory pain, of course, non-steroidal anti-inflammatory drugs (NSAIDs) are preferred, but it is worth remembering that there is no class effect in this group, which in practice means that when choosing a specific drug, we must know its pharmacokinetic and pharmacodynamic profile. One of the drugs that is highly effective in the treatment of inflammatory pain is etoricoxib. The paper discusses the current indications and safety profile of etoricoxib in clinical practice.
Article Details
How to Cite
Woroń , J. (2023). Etoricoxib benefit map. Medycyna Faktow (J EBM), 16(4(61), 305-309. https://doi.org/10.24292/01.MF.0423.02
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wordliczek J, Woroń J, Targońska-Stępniak B et al. Leczenie bólu zapalnego – problem interdyscyplinarny widziany oczami reumatologa, neurologa, rehabilitanta, specjalisty medycyny bólu i farmakologa klinicznego. Ból. 2018; 19(4): 11-26.
2. Dobrogowski J, Wordliczek J, Woroń J (ed). Farmakoterapia bólu, Termedia, Poznań 2014.
3. Bajwa ZH, Wootton RJ, Warfield CA. Principles and Practice of Pain Medicine. McGrawHill, New York 2017.
4. Malec-Milewska M, Woroń J. Kompendium leczenia bólu. Medical Education, Warszawa 2017.
5. DiPiro JT, Talbert RL, Yee GC et al. Pharmacotherapy. McGrawHill, New York 2020.
6. Woroń J. Korzystne i niekorzystne interakcje leków stosowanych w farmakoterapii bólu. Medical Education, Warszawa 2018.
7. Fine P. Chronic pain management in older adults: Special considerations. J Pain Symptom Manage. 2009; 38(2 Suppl): S4-S14. http://doi.org/10.1016/j.jpainsymman.2009.05.002.
8. Gustorff B, Dorner T, Likar R et al. Prevalence of self-reported neuropathic pain and impact on quality of life: A prospective representative survey. Acta Anaesthesiol Scand. 2008; 52(1): 132-6. https://doi.org/10.1111/j.1399-6576.2007.01486.x.
9. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002; 50(6 Suppl): S205-24.
10. Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? Drugs Aging. 2005; 22(3): 185-200. https://doi.org/10.2165/00002512-200522030-00001.
11. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol. 2002; 14(5): 573-7. https://doi.org/10.1097/00002281-200209000-00017.
12. Puopolo A, Boice J, Fidelholtz J et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007; 15(12): 1348-56. https://doi.org/10.1016/j.joca.2007.05.022.
13. Elliott A, Smith B, Penny K et al. The epidemiology of chronic pain in the community. Lancet. 1999; 354(9186): 1248-52. https://doi.org/10.1016/S0140-6736(99)03057-3.
14. McDonough CM, Jette AM. The contribution of osteoarthritis to functional limitations and disability. Clin Geriatr Med. 2010; 26(3): 387-99. https://doi.org/10.1016/j.cger.2010.04.001.
15. Zambon S, Siviero P, Denkinger M et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. Arthritis Care Res (Hoboken). 2016; 68(6): 801-10. https://doi.org/10.1002/acr.22755.
16. Breedveld FC. Osteoarthritis – the impact of a serious disease. Rheumatology (Oxford). 2004; 43 Suppl 1: i4-8. https://doi.org/10.1093/rheumatology/keh102.
17. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003; 81(9): 646-56.
18. Landi F, Russo A, Liperoti R et al. Daily pain and functional decline among old-old adults living in the community: results from the ilSIRENTE Study. J Pain Symptom Manage. 2009; 38(3): 350-7. https://doi.org/10.1016/j.jpainsymman.2008.10.005.
19. Balsam P. Bezpieczeństwo kardiologiczne stosowania etorykoksybu. Medycyna Faktów 2023; 16(58): 99-104.
2. Dobrogowski J, Wordliczek J, Woroń J (ed). Farmakoterapia bólu, Termedia, Poznań 2014.
3. Bajwa ZH, Wootton RJ, Warfield CA. Principles and Practice of Pain Medicine. McGrawHill, New York 2017.
4. Malec-Milewska M, Woroń J. Kompendium leczenia bólu. Medical Education, Warszawa 2017.
5. DiPiro JT, Talbert RL, Yee GC et al. Pharmacotherapy. McGrawHill, New York 2020.
6. Woroń J. Korzystne i niekorzystne interakcje leków stosowanych w farmakoterapii bólu. Medical Education, Warszawa 2018.
7. Fine P. Chronic pain management in older adults: Special considerations. J Pain Symptom Manage. 2009; 38(2 Suppl): S4-S14. http://doi.org/10.1016/j.jpainsymman.2009.05.002.
8. Gustorff B, Dorner T, Likar R et al. Prevalence of self-reported neuropathic pain and impact on quality of life: A prospective representative survey. Acta Anaesthesiol Scand. 2008; 52(1): 132-6. https://doi.org/10.1111/j.1399-6576.2007.01486.x.
9. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002; 50(6 Suppl): S205-24.
10. Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? Drugs Aging. 2005; 22(3): 185-200. https://doi.org/10.2165/00002512-200522030-00001.
11. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol. 2002; 14(5): 573-7. https://doi.org/10.1097/00002281-200209000-00017.
12. Puopolo A, Boice J, Fidelholtz J et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007; 15(12): 1348-56. https://doi.org/10.1016/j.joca.2007.05.022.
13. Elliott A, Smith B, Penny K et al. The epidemiology of chronic pain in the community. Lancet. 1999; 354(9186): 1248-52. https://doi.org/10.1016/S0140-6736(99)03057-3.
14. McDonough CM, Jette AM. The contribution of osteoarthritis to functional limitations and disability. Clin Geriatr Med. 2010; 26(3): 387-99. https://doi.org/10.1016/j.cger.2010.04.001.
15. Zambon S, Siviero P, Denkinger M et al. Role of Osteoarthritis, Comorbidity, and Pain in Determining Functional Limitations in Older Populations: European Project on Osteoarthritis. Arthritis Care Res (Hoboken). 2016; 68(6): 801-10. https://doi.org/10.1002/acr.22755.
16. Breedveld FC. Osteoarthritis – the impact of a serious disease. Rheumatology (Oxford). 2004; 43 Suppl 1: i4-8. https://doi.org/10.1093/rheumatology/keh102.
17. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003; 81(9): 646-56.
18. Landi F, Russo A, Liperoti R et al. Daily pain and functional decline among old-old adults living in the community: results from the ilSIRENTE Study. J Pain Symptom Manage. 2009; 38(3): 350-7. https://doi.org/10.1016/j.jpainsymman.2008.10.005.
19. Balsam P. Bezpieczeństwo kardiologiczne stosowania etorykoksybu. Medycyna Faktów 2023; 16(58): 99-104.